Humacyte, Inc.

NASDAQ:HUMA

Biotechnology

Healthcare
$0.50 -3.35%

-$0.03 today

Market cap
$138.90M
Beta
2.46
P/E (TTM)
-1.9
EPS (TTM)
-$0.49
52W Low $0.55High $2.84

Volume 3.91M

Average 8.14M

HUMA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Humacyte, Inc.NASDAQ: HUMA

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $3.17M rose 27.5% year over year, behind the +45.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 28.3% from the prior quarter. Over 3 fiscal years it compounded at +16.4% a year.

Context

  • Stock-based compensation amounted to 478.6% of revenue in FY2025.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +27.5% toward the trailing-twelve-month pace of +45.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.17M+28.3% QoQ
Last fiscal yearDec 2025
$9.75M+58.9% YoY
LTMMar 2026
$10.44M+45.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.5%——
1 year+58.9%——
3-year CAGR+16.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
9.75M USD
Year-over-year change
+58.9%
4-year CAGR
-1.0%

Stock-Based Compensation vs competitors

How HUMA compares with its peers on the latest reported figures

  • HUMA's LTM Mar 2026 stock-based compensation of $10.44M is the 5th largest of the 11 companies compared; the peer median is $8.21M.
  • Its year-over-year change of +45.6% is the highest of 11, against a peer median of -16.0%.
  • Stock-based compensation amounts to 517.7% of revenue for HUMA, versus a peer median of 37.3%.
HUMA Competitors Peer median
Stock-Based Compensation for HUMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$23.07M -33.2%-6.0%50.9%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$19.27M -0.0%+25.6%335.8%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$17.5M -62.1%-23.7%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$13.6M -8.6%+16.5%37.3%
HUMAHumacyte, Inc.LTM Mar 2026$10.44M +45.6%+16.4%517.7%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$9.07M -23.3%-16.5%4.2%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$7.36M +42.2%—26.1%
SGMTSagimet Biosciences Inc.LTM Mar 2026$6.82M +13.6%+50.8%—
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$6.04M -48.6%-13.0%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$5.84M -6.8%+38.9%—
IMRXImmuneering CorporationLTM Mar 2026$1.52M -69.5%——
Peer median (excluding HUMA) $8.21M-16.0%+5.3%37.3%

Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.48M)(11.97M)(110.78M)(148.7M)(40.83M)
Depreciation & Amortization8.24M8.21M7.72M7.19M5.33M
Deferred Income Tax00000
Stock-Based Compensation10.15M6.18M6.83M6.14M9.75M
Change in Working Capital(557K)1.03M6.57M311K(23.4M)
Accounts Receivables(63K)145K31K0(261K)
Inventory0000(21.83M)
Accounts Payables(197K)(509K)4.81M(1.96M)973K
Other Working Capital(297K)1.39M1.73M2.27M(2.28M)
Other Non-Cash Items(72.54M)(74.59M)16.35M36.94M(55.9M)
Operating Cash Flow(81.19M)(71.13M)(73.31M)(98.12M)(105.04M)
Capital Expenditures(220K)(1.05M)(2.28M)(1.57M)(884K)
Acquisitions (Net)00000
Purchases of Investments(8M)(10.11M)000
Sales of Investments016M2.11M00
Other Investing Activities00000
Investing Cash Flow(8.22M)4.85M(173K)(1.57M)(884K)
Debt Repayment27.93M(1.98M)5.7M(2.58M)36.39M
Common Stock Issued598K535K566K45.93M113.44M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities239.05M535K(1.76M)27.71M(88.34M)
Financing Cash Flow266.98M(1.45M)4.51M114.18M61.49M
Effect of Forex Changes00(209K)00
Net Change in Cash177.57M(67.73M)(69.18M)14.49M(44.44M)
Free Cash Flow(81.41M)(72.18M)(75.59M)(99.69M)(105.93M)

Humacyte, Inc.

NASDAQ:HUMA

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.